[关键词]
[摘要]
视网膜新生血管性疾病的共同特征是病理性新生血管形成。目前研究的内源性视网膜新生血管因子最主要的是VEGF。可溶性VEGF受体1(sFlt-1)是VEGFR-1的mRNA胞外区剪接形成的可溶性形式，只编码胞外区，缺乏细胞内酪氨酸激酶区域，所以其仅具有与配体结合的能力，而无信号转导能力，从而阻止新生血管的形成。sFlt-1作为近年来的研究热点，有可能成为治疗该类疾病的新的基因治疗方法。本文就sFlt-1在视网膜新生血管疾病治疗中的作用机制及研究进展做一综述。
[Key word]
[Abstract]
The common feature of retinal neovascularization is the formation of pathological neovascularization. The primary one of endogenous retinal neovascularization factor in current research is vascular endothelial growth factor(VEGF). SFlt-1, the soluble form of splicing in mRNA extracellular region of VEGFR-1, which is short of intracellular tyrosine kinase domain can only encode the extracellular domain. Therefore, it only can bind with ligands but can not transmit signals, thus preventing the formation of neovascularization. SFlt-1, as a hot research topic in recent years, may provide a new gene therapy method for this disease. This review focus on the mechanism and research progress of sFlt-1 in retinal neovascularization.
[中图分类号]
[基金项目]
福建省社会发展高校产学合作项目(No.2014Y4003)
